Panbela Therapeutics (PBLA) Competitors $0.41 +0.04 (+10.51%) As of 01/21/2025 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends PBLA vs. VRAX, ABVC, EYEN, GLTO, VIRX, ORGS, EVOK, GRI, ALZN, and SPRCShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Virax Biolabs Group (VRAX), ABVC BioPharma (ABVC), Eyenovia (EYEN), Galecto (GLTO), Viracta Therapeutics (VIRX), Orgenesis (ORGS), Evoke Pharma (EVOK), GRI Bio (GRI), Alzamend Neuro (ALZN), and SciSparc (SPRC). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Virax Biolabs Group ABVC BioPharma Eyenovia Galecto Viracta Therapeutics Orgenesis Evoke Pharma GRI Bio Alzamend Neuro SciSparc Panbela Therapeutics (NASDAQ:PBLA) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Do analysts prefer PBLA or VRAX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, PBLA or VRAX? Virax Biolabs Group has higher revenue and earnings than Panbela Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$71.13-0.01Virax Biolabs Group$160K42.19-$6.73MN/AN/A Does the MarketBeat Community prefer PBLA or VRAX? Panbela Therapeutics received 18 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. CompanyUnderperformOutperformPanbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% Virax Biolabs GroupN/AN/A Do institutionals and insiders hold more shares of PBLA or VRAX? 4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PBLA or VRAX more profitable? Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -302.61% Virax Biolabs Group N/A N/A N/A Which has more volatility & risk, PBLA or VRAX? Panbela Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Does the media prefer PBLA or VRAX? In the previous week, Panbela Therapeutics' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score. Company Overall Sentiment Panbela Therapeutics Neutral Virax Biolabs Group Neutral SummaryVirax Biolabs Group beats Panbela Therapeutics on 6 of the 9 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99M$6.58B$5.40B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.0110.0188.8317.53Price / SalesN/A335.371,284.8780.52Price / CashN/A22.6336.6032.90Price / Book-0.025.084.964.69Net Income-$25.26M$154.90M$117.89M$224.57M7 Day Performance13.26%2.59%2.74%3.33%1 Month Performance26.15%1.52%3.63%5.33%1 Year Performance-94.03%5.49%27.26%22.97% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela TherapeuticsN/A$0.41+10.5%N/A-94.0%$1.99MN/A-0.016Gap DownVRAXVirax Biolabs Group0.2559 of 5 stars$2.18+1.9%N/A+99.0%$7.04M$160,000.000.005Gap UpABVCABVC BioPharma0.9018 of 5 stars$0.54-2.0%N/A-56.7%$7.01M$150,000.00-0.6330EYENEyenovia2.6803 of 5 stars$0.06-5.2%$2.00+3,094.9%-96.1%$6.98MN/A-0.0940Gap DownGLTOGalecto3.3067 of 5 stars$5.26+13.7%$10.00+90.0%-65.0%$6.95MN/A-0.2840Positive NewsHigh Trading VolumeVIRXViracta Therapeutics2.666 of 5 stars$0.17-6.1%$4.05+2,297.9%-67.4%$6.71MN/A-0.1520ORGSOrgenesisN/A$1.39-13.1%N/AN/A$6.67M$530,000.000.00150Gap DownEVOKEvoke Pharma0.812 of 5 stars$4.37-2.1%N/A-51.7%$6.50M$5.18M-0.404Positive NewsGRIGRI Bio2.7651 of 5 stars$0.72+2.1%$11.50+1,496.6%-97.2%$6.43MN/A0.001ALZNAlzamend Neuro2.3283 of 5 stars$1.16+0.9%$32.00+2,658.6%-86.6%$6.30MN/A0.004Positive NewsSPRCSciSparc0.4706 of 5 stars$0.60-16.8%N/A-83.8%$6.21M$2.88M0.004Gap Down Related Companies and Tools Related Companies Virax Biolabs Group Competitors ABVC BioPharma Competitors Eyenovia Competitors Galecto Competitors Viracta Therapeutics Competitors Orgenesis Competitors Evoke Pharma Competitors GRI Bio Competitors Alzamend Neuro Competitors SciSparc Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBLA) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBLA Stock Alerts